MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.770
+0.190
+5.31%
Closed 17:26 07/05 EDT
OPEN
3.500
PREV CLOSE
3.580
HIGH
3.940
LOW
3.440
VOLUME
87.85K
TURNOVER
0
52 WEEK HIGH
22.50
52 WEEK LOW
3.030
MARKET CAP
18.88M
P/E (TTM)
-0.6115
1D
5D
1M
3M
1Y
5Y
Aptevo Therapeutics's Return On Capital Employed Overview
Benzinga Pro data, Aptevo Therapeutics (NASDAQ:APVO) reported Q1 sales of $3.11 million. Earnings fell to a loss of $7.70 million, resulting in a 22.72% decrease from last quarter.
Benzinga · 06/17 15:04
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
Aptevo gains after disclosing additional remission data in leukemia trial
Aptevo Therapeutics (NASDAQ:APVO) traded higher in the morning hours Thursday after the clinical-stage biotech announced new remission data on four additional patients enrolled in its Phase 1b expansion trial for
Seekingalpha · 06/09 13:35
Aptevo Therapeutics Announces New Preliminary Remission Data On Four Additional Patients Enrolled In On-going APVO436 Dose Expansion Phase 1B Trial For The Treatment Of Acute Myeloid Leukemia
Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myelodysplastic
Benzinga · 06/09 12:13
--Piper Sandler Adjusts Price Target on Aptevo Therapeutics to $20 From $69, Reiterates Overweight Rating
MT Newswires · 05/13 09:16
Recap: Aptevo Therapeutics Q1 Earnings
  Aptevo Therapeutics (NASDAQ:APVO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/12 13:49
Aptevo Therapeutics GAAP EPS of -$1.59 misses by $0.66, revenue of $3.11M misses by $0.64M
Aptevo Therapeutics press release (NASDAQ:APVO): Q1 GAAP EPS of -$1.59 misses by $0.66. Revenue of $3.11M (+28.5% Y/Y) misses by $0.64M.
Seekingalpha · 05/12 12:45
BRIEF-Aptevo Therapeutics Reports Quarterly Loss Per Share $1.55
reuters.com · 05/12 12:18
More
No Data
Learn about the latest financial forecast of APVO. Analyze the recent business situations of Aptevo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average APVO stock price target is 28.00 with a high estimate of 36.00 and a low estimate of 20.00.
High36.00
Average28.00
Low20.00
Current 3.770
EPS
Actual
Estimate
-1.60-1.20-0.80-0.40
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 54
Institutional Holdings: 3.81M
% Owned: 76.10%
Shares Outstanding: 5.01M
TypeInstitutionsShares
Increased
3
29.51K
New
5
112.62K
Decreased
6
85.77K
Sold Out
4
5.31K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About APVO
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. It has developed two platform technologies, such as ADAPTIR and ADAPTIR-FLEX for rational design of precision immune modulatory drugs. Its lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is being developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific CD3xCD123 ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate employing a mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.